Kiora Pharmaceuticals Inc. has announced a strategic partnership with Senju Pharmaceutical Co., Ltd. granting Senju an exclusive option for the development and commercialization of KIO-301, aimed at treating ophthalmic diseases, across key Asian markets including Japan and China. The total potential deal value is estimated to be $110 million, in addition to tiered royalties on sales. Kiora is set to receive an immediate $1.25 million fee for this exclusive option, and should Senju exercise the option, Kiora will obtain a further mid-single digit million up-front payment along with development, regulatory, and commercial milestones. This agreement strengthens Kiora's global commercial reach, complementing their ongoing partnership with Théa outside of Asia, and highlights the demand for innovative treatments for retinal conditions such as retinitis pigmentosa.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.